Drug Profile
Research programme: macrocyclic peptide therapeutics - PeptiDream/ Sanofi
Latest Information Update: 28 Oct 2019
Price :
$50
*
At a glance
- Originator PeptiDream
- Developer PeptiDream; Sanofi
- Class Macrocyclic compounds; Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Oct 2019 No recent reports of development identified for research development in Unspecified in Japan
- 14 Sep 2015 Early research in Undefined indication in Japan (unspecified route)